Citizens Maintains Market Outperform on Rhythm Pharmaceuticals, Raises Price Target to $166
Benzinga Newsdesk 13 hours ago
Analyst RatingsNewsPrice Target
Citizens analyst Jonathan Wolleben maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Market Outperform and raises the price target from $160 to $166.
Citizens analyst Jonathan Wolleben maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Market Outperform and raises the price target from $160 to $166.